Ky­owa Kirin pulls the plug on drug de­vel­op­ment for suc­ces­sor to Parkin­son's drug Nouri­anz

Three years af­ter Japan’s Ky­owa Kirin se­cured FDA ap­proval for an add-on ther­a­py to lev­odopa in Parkin­son’s, the com­pa­ny has scrapped its po­ten­tial suc­ces­sor.

Ky­owa Kirin is­sued a short state­ment Fri­day on the new de­vel­op­ment af­ter con­duct­ing two Phase II stud­ies in Japan: an ear­ly Phase II with 175 par­tic­i­pants fin­ished in 2017, and a Phase IIb with 502 par­tic­i­pants that con­clud­ed in 2020. The com­pa­ny said those stud­ies pro­vid­ed a sig­nal the drug could be po­ten­tial­ly ef­fec­tive in Parkin­son’s by it­self and as a com­bi­na­tion ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER